Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Inari Medical (NARI): What Makes it’s a Prime Acquisition Target ?
Inari Medical (NARI) continues to solidify its leadership in the underpenetrated vascular intervention market, reporting Q3 2024 revenue of $153.4M (+21.4% YoY) with broad-based growth across U.S. VTE (+19.7%), Emerging Therapies (+64%), and International (+76.4%). This reflects its strategic focus on diversifying growth drivers and leveraging a differentiated portfolio. Industry-leading gross margins of 87.1% and disciplined operational execution underscore its profitability potential, even as heightened SG&A and R&D investments position the company for sustained long-term growth. Emerging Therapies like LimFlow and Artix, alongside the anticipated PEERLESS trial data, highlight its robust pipeline targeting unmet needs in venous and vascular diseases. International expansion, bolstered by regulatory approvals in China and Japan and a joint venture with VFLO Medical, provides a pathway to scale globally and meet its target of international revenue contributing 20% in coming years. Management’s raised FY2024 revenue guidance and visibility into a $1B TAM for chronic venous disease further strengthen its growth outlook. While operational intensity and adoption lags pose near-term risks, Inari’s innovation and market leadership position it as a compelling acquisition target for medtech players seeking growth in high-margin, high-growth therapeutic areas. How might Inari best navigate its operational challenges to fully realize its global potential?
